Inspira Technologies Oxy BHN Ltd
Inspira Technologies Oxy BHN Ltd designs, develops, and commercializes advanced medical equipment and technology solutions, primarily serving the healthcare services and equipment sector.
Business. Inspira Technologies Oxy BHN Ltd (IINN.O) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm engages in the sale of healthcare equipment and is listed on the NASDAQ exchange. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Inspira Technologies Oxy BHN Ltd (IINN.O) is a healthcare company operating in the Advanced Medical Equipment & Technology industry. The firm engages in the sale of healthcare equipment and is listed on the NASDAQ exchange. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data.
Inspira Technologies Oxy BHN Ltd maintains a strong liquidity position, with $3.16 million in cash and equivalents, representing 59.1% of total assets. The company has no long-term debt and a current ratio of 1.56, indicating sufficient short-term liquidity to cover obligations. However, the firm reported negative operating and free cash flows of -$9.86 million and -$12.87 million, respectively, signaling ongoing operational cash burn.
Profitability metrics are severely negative, with a net loss of $13.22 million and an operating loss of $13.62 million. Return on equity (ROE) and return on assets (ROA) are -5.69% and -2.48%, respectively, far below the industry median for advanced medical equipment firms. The company's price-to-book ratio of 8.38 and enterprise value-to-revenue ratio of 56.45 suggest a premium valuation relative to tangible asset base and revenue, despite unprofitable operations.
The firm operates as a single-segment entity with no disclosed geographic revenue breakdown. This lack of diversification introduces concentration risk, as the company's performance is entirely dependent on its core product lines and regional demand. No material revenue concentration by geography or customer is reported in the latest filings.
Growth prospects remain uncertain, with no revenue growth reported in the latest period. The company's operating losses and negative cash flows indicate a lack of scalable revenue generation. Analysts have assigned a mean price target of $5.00, implying a 1,000% upside from the current market price of $0.45, though this is based on a single "buy" recommendation with no supporting detail.
Risk factors include liquidity risk from negative operating cash flows and dilution risk from potential future equity raises to fund operations. The firm has no immediate filing-based liquidity or dilution flags, but its capital structure shows no dilution in the current period (basic and diluted shares are equal). No adjustments were applied to valuation metrics, indicating clean financial reporting.
Recent events include the publication of the latest financial snapshot, which shows continued operational losses and no material changes in capital structure. No recent filings, transcripts, or regulatory actions were identified in the available data.
- Inspira Technologies Oxy BHN Ltd is a loss-making advanced medical equipment firm with a premium valuation despite negative cash flows and returns.
- The company's liquidity position is strong in absolute terms but unsustainable given ongoing operational cash burn.
- Analysts have assigned a high price target, but the recommendation is based on a single "buy" rating with no supporting detail.
- The firm's lack of geographic or segment diversification introduces concentration risk.
- No immediate liquidity or dilution flags are present, but future equity raises may be necessary to fund operations.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,11 |
| Revenue | —no estimate | —no estimate | 48,0M USD |
| Operating income | —no estimate | —no estimate | 4,2M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Inspira Technologies Oxy BHN Ltd Market data — financials · 2026-05-28
- Inspira Technologies Oxy BHN Ltd Market data — analyst estimates · 2026-05-28
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 18.6%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -20.9%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -33.8%Derived (calculated)
- Return on assets (FY 2025-12-31): -247.5%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -5.2%Derived (calculated)
- Current ratio (FY 2025-12-31): 1.56xDerived (calculated)
- Net margin (FY 2025-12-31): -4,574.4%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -37.2%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 25.0%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -19.6%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 25.0%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -46.3%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -38.2%Derived (calculated)
- Gross margin (FY 2025-12-31): 0.7%Derived (calculated)
- Return on equity (FY 2025-12-31): -569.1%Derived (calculated)
- Net income (annual): USD -13.22MSEC XBRL filing
- Revenue (annual): USD 289KSEC XBRL filing
- Gross profit (annual): USD 2KSEC XBRL filing
- Shareholders' equity (annual): USD 2.32MSEC XBRL filing
- Total assets (annual): USD 5.34MSEC XBRL filing
- Operating income (annual): USD -13.62MSEC XBRL filing
- R&D expense (annual): USD 7.5MSEC XBRL filing
- Operating cash flow (annual): USD -9.86MSEC XBRL filing
- Current liabilities (annual): USD 2.82MSEC XBRL filing